News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Degussa's Exceptional Market Penetration Strategies Recognised By Frost & Sullivan

10/19/2005 5:12:29 PM

LONDON, September 22 /PRNewswire/ -- Degussa AG has been selected to receive the '2004 Frost & Sullivan Market Penetration Leadership Award' for its demonstrated excellence in product and process innovation leveraged by strong manufacturing capabilities, project management skills and marketing and sales strategies. All of these have lead to significant market share gains for Degussa, particularly in the European market of active pharmaceutical ingredients (API). "In analysing market penetration, Degussa has managed to build a critical standing in the European custom manufacturing market as one of the leaders in multiple product and service offerings for the pharma industry," says Mr. Himanshu Parmar, Industry Analyst with Frost & Sullivan. "This, coupled with an experienced staff and long-term vision, is pushing Degussa's sustained rapid growth and success in this highly fragmented and competitive market environment."

Following its recent establishment in 2001 as a result of the merger of Degussa-Huls AG and SKW Trostberg AG, the "new" Degussa has been able to dramatically improve its revenue. The company as a whole is presently the world's market leader in speciality chemicals with total sales of Euro 11.2 billion during 2004.

Alliances and acquisitions have been central to Degussa's successful market penetration strategies. In 2001, Degussa acquired Laporte plc. (the British speciality chemicals company) thereby significantly strengthening its technology and marketing expertise, specifically in the custom manufacturing segment.

"Close collaborations with world-class pharmaceuticals and biotechnology companies have reinforced Degussa's reputation for exceptional technology, quality and service," notes Mr. Parmar. "Moreover, clients value the company's open and transparent style of functioning. This observation is fully in line with Degussa's given promise to deliver substantial 'solutions to customers' - and delivering on promises is always well received by the markets."

Besides Degussa's well established relationships to big pharma companies, another emphasis is set on cooperating with small but emerging pharmaceuticals companies to effect profitable growth also in the long run. This is because, typically, such so-called "virtual" pharmaceuticals companies usually have a strong intellectual property portfolio but sometimes lack manufacturing capacities of their own.

An innovative research concept known as 'Project Houses' supports collaborative endeavours between Degussa's experts with external partners from universities and industry in areas of high interest for the whole industry, e.g. biotechnology, functional polymers, nanotechnology and catalysts. This approach has enabled the company to evaluate and identify the latest technological trends, sustain its innovation and research activities by targeted investments at manageable costs and boosted its image as an innovation-oriented company.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics and demographics. For more information, visit

Media Contact: Katja Feick, Corporate Communications, Frost & Sullivan, Phone: +49-69-77033-12, Fax: +49-69-234566, E-Mail:

Frost & Sullivan

CONTACT: Katja Feick, Corporate Communications, Frost & Sullivan, Phone:+49-69-77033-12, Fax: +49-69-234566, E-Mail:

Read at

comments powered by Disqus